Biotechnology
Commented by Armin Schulz on April 30th, 2026 | 07:00 CEST
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec
The healthcare market faces a paradoxical scenario in 2026. Public health funds are groaning under record spending, while groundbreaking technologies are redefining medicine. AI-driven drug discovery and personalized therapies promise efficiency gains, but regulatory hurdles and price wars are causing stock prices to fluctuate. In this complex landscape, the wheat is being separated from the chaff. Three distinct biotech strategies could now provide the decisive edge. Novo Nordisk dominates the mass market for metabolic diseases, Vidac Pharma is tackling cancer in novel ways, and Evotec is digitizing the entire drug discovery process.
Read
Commented by André Will-Laudien on April 21st, 2026 | 06:55 CEST
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight
The Middle East conflict is once again bringing global supply chains into focus and increasing pressure on vulnerable supply routes. The Strait of Hormuz, in particular, remains a key geopolitical risk factor because it is of great importance for the global flow of goods and energy. If tensions arise there, transportation costs, delivery times, and price fluctuations can quickly escalate. This creates new opportunities as well as risks, particularly for companies involved in food, health, and agricultural technology. MustGrow and K+S ensure the global food supply through fertilizers, while Evotec and BioNTech operate in the complex landscape of health-related issues. Despite uncertain conditions, dynamic investors are keeping an eye on the stocks that deliver comparatively robust results in a volatile market environment. We dig a little deeper!
Read
Commented by Fabian Lorenz on April 20th, 2026 | 08:10 CEST
Insider Sales, Buy Ratings, and AI Momentum: BioNTech, Evotec, and Vidac Pharma in Focus
Insider sales at Vidac Pharma. However, this is not necessarily a cause for concern and may rather present a potential entry opportunity. The company is working on a revolutionary cancer therapy, with key milestones expected in 2026. Analysts see significant upside potential, and there is also speculation about a possible takeover. AI-driven expectations are giving Evotec shares new momentum. Analysts recommend buying the stock, although there are also reasons for caution. At BioNTech, the market appears to have absorbed the impact of the founders' departure. Following positive study data, analysts see further upside potential.
Read
Commented by Mario Hose on April 13th, 2026 | 07:30 CEST
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec
Even in the spring of 2026, the stock market remains highly volatile. The upheavals caused by geopolitical crises have been and remain significant and ever-present. While heavyweights like Bayer are struggling to shake off their legal baggage and Evotec is steering into calmer waters, a stock from the back row is suddenly stepping into the spotlight. Vidac Pharma has also had a few turbulent months, and this is precisely where experienced investors now sense an opportunity. With a current share price of EUR 0.56, the company is poised for a potential recovery, an uptick, and perhaps even a complete revaluation. If the strategy pays off, the EUR 1 mark could be reached. That would be a chance to double their money for bold investors. But what is behind this optimism? In this report, we take a look at the industry giants and analyze not only them but also why, of all three, the one with the smallest market capitalization could develop the greatest momentum. It is about potential breakthroughs in cancer research and a management team that is optimizing many aspects for success.
Read
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by Stefan Feulner on April 2nd, 2026 | 07:05 CEST
SAP, Desert Gold, Novo Nordisk – Strong Rebound Potential
Donald Trump's surprise announcement that he intends to end the Iran conflict is sparking renewed activity in the markets. After weeks of uncertainty and, in some cases, sharp price declines, sentiment is noticeably improving. Many stocks had previously suffered from geopolitical pressure but could now be poised for a strong rebound. Investors are increasingly looking toward a possible easing of tensions, falling risk premiums, and a return of capital to riskier asset classes.
Read
Commented by Mario Hose on April 1st, 2026 | 07:00 CEST
Vonovia, Novo Nordisk, and Lahontan Gold: Choose between concrete gold, weight-loss hype, and Nevada's treasure!
The capital market in the spring of 2026 is a whirlwind of emotions. Real estate stocks are struggling to regain ground after the interest rate freeze. In the pharmaceutical sector, a Danish giant is under pressure and has made headlines. Away from the big stage, a smaller player in the mining sector is emerging, one that, after a consolidation phase, now aims to head north. In this report, we take a look at the real estate group Vonovia and the pharmaceutical weight-loss specialist Novo Nordisk. Both stocks have had turbulent months and could now begin to regain lost ground. Another focus is on Lahontan Gold. The Nevada-based company has recently made important strategic moves. Following a financing round, the stock price has stalled briefly. However, the latest exploration news suggests that the stock could now regain strong momentum.
Read
Commented by Nico Popp on March 30th, 2026 | 08:30 CEST
A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma
Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.
Read
Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer
The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.
Read
Commented by Armin Schulz on March 20th, 2026 | 08:35 CET
Act Now! Invest in cancer research with BioNTech, Vidac Pharma, and Pfizer and secure returns
Global healthcare spending is surging, and the oncology sector promises above-average returns. As the global population continues to age, the number of new cancer cases is expected to rise to over 30 million annually by 2040, intensifying competition among pharmaceutical companies for market share in this trillion-dollar industry. However, it is not yesterday's established drugs that offer the greatest profit potential, but rather radical technological shifts. While BioNTech is now deploying its billion-dollar mRNA platform against tumors, Vidac Pharma is pursuing an entirely novel approach aimed at starving cancer cells. At the same time, Pfizer is pushing aggressively into this field. We take a closer look at the current situation of these three companies.
Read